Intensity Therapeutics, Inc. (INTS)Healthcare | Biotechnology | Shelton, United States | NasdaqCM
5.30 USD
-0.02
(-0.376%) ⇩
(April 17, 2026, 4 p.m.
EDT)
After hours: 5.26 -0.04 (-0.040%) ⇩ (April 17, 2026, 7:45 p.m. EDT) Short-term: ★★☆☆☆ | Long-term: ★☆☆☆☆ | Dividends: ☆☆☆☆☆ |
Hot Take | April 11, 2026, 3:58 p.m. EDT
INTS is a high-beta stock with a significant amount of volatility, which makes it unsuitable for short-term trading. The recent price history shows a downward trend, with the current price at $5.50, which is close to its 52-week low of $4.625. The stock's forward P/E is negative, indicating potential earnings issues, and the trailing EPS is also negative. While the stock has some positive news, such as clinical trial results and a rating upgrade, the fundamentals are weak, and the stock is not a good candidate for long-term investment. Additionally, there are no dividends to consider, making it unsuitable for dividend investors. |
| Model | MAE |
|---|---|
| AutoTheta ✓ | 0.287991 |
| AutoARIMA | 0.405910 |
| AutoETS | 0.406094 |
| MSTL | 0.406996 |
Forecast horizon: 45 days | Selected: AutoTheta
| Forecast Reliability | |
|---|---|
| Score | 45% |
| H-stat | 8.36 |
| Ljung-Box p | 0.000 |
| Jarque-Bera p | 0.150 |
| Excess Kurtosis | -1.41 |
| Attribute | Value |
|---|---|
| Sector | Healthcare |
| Debt to Equity Ratio | 0.926 |
| Market Cap | 13,464,746 |
| Forward P/E | -1.80 |
| Beta | 4.23 |
| Website | https://www.intensitytherapeutics.com |
| Attribute | Value |
|---|---|
| 52 Week Change | -0.8903093 |
| Address1 | 1 Enterprise Drive |
| Address2 | Suite 430 |
| All Time High | 286.0 |
| All Time Low | 4.625 |
| Ask | 6.66 |
| Ask Size | 2 |
| Average Analyst Rating | 1.0 - Strong Buy |
| Average Daily Volume10 Day | 26,340 |
| Average Daily Volume3 Month | 50,085 |
| Average Volume | 50,085 |
| Average Volume10Days | 26,340 |
| Beta | 4.232 |
| Bid | 3.89 |
| Bid Size | 2 |
| Book Value | 4.704 |
| City | Shelton |
| Compensation As Of Epoch Date | 1,767,139,200 |
| Country | United States |
| Crypto Tradeable | 0 |
| Currency | USD |
| Current Price | 5.3 |
| Current Ratio | 5.922 |
| Custom Price Alert Confidence | HIGH |
| Date Short Interest | 1,774,915,200 |
| Day High | 5.42 |
| Day Low | 5.2 |
| Debt To Equity | 0.926 |
| Display Name | Intensity Therapeutics |
| Earnings Timestamp End | 1,754,596,800 |
| Earnings Timestamp Start | 1,754,596,800 |
| Ebitda Margins | 0.0 |
| Enterprise Value | 1,653,745 |
| Eps Current Year | -3.60333 |
| Eps Forward | -2.95 |
| Eps Trailing Twelve Months | -8.56 |
| Esg Populated | 0 |
| Exchange | NCM |
| Exchange Data Delayed By | 0 |
| Exchange Timezone Name | America/New_York |
| Exchange Timezone Short Name | EDT |
| Fax | 203 557 3023 |
| Fifty Day Average | 6.78368 |
| Fifty Day Average Change | -1.4836798 |
| Fifty Day Average Change Percent | -0.21871312 |
| Fifty Two Week Change Percent | -89.03093 |
| Fifty Two Week High | 48.55 |
| Fifty Two Week High Change | -43.25 |
| Fifty Two Week High Change Percent | -0.8908342 |
| Fifty Two Week Low | 4.625 |
| Fifty Two Week Low Change | 0.6750002 |
| Fifty Two Week Low Change Percent | 0.14594598 |
| Fifty Two Week Range | 4.625 - 48.55 |
| Financial Currency | USD |
| First Trade Date Milliseconds | 1,688,131,800,000 |
| Float Shares | 2,319,366 |
| Forward Eps | -2.95 |
| Forward P E | -1.7966102 |
| Free Cashflow | -5,109,500 |
| Full Exchange Name | NasdaqCM |
| Full Time Employees | 5 |
| Gmt Off Set Milliseconds | -14,400,000 |
| Gross Margins | 0.0 |
| Has Pre Post Market Data | 1 |
| Held Percent Insiders | 0.08705 |
| Held Percent Institutions | 0.079959996 |
| Implied Shares Outstanding | 2,540,518 |
| Industry | Biotechnology |
| Industry Disp | Biotechnology |
| Industry Key | biotechnology |
| Ipo Expected Date | 2,023-06-30 |
| Is Earnings Date Estimate | 1 |
| Language | en-US |
| Last Fiscal Year End | 1,767,139,200 |
| Last Split Date | 1,771,459,200 |
| Last Split Factor | 1:25 |
| Long Business Summary | Intensity Therapeutics, Inc., a late-stage clinical biotechnology company, engages in the provision of treatment for the regional and systemic nature of cancer in the United States. Its lead product candidate includes INT230-6, which is in Phase 3 clinical studies for the treatment of soft tissue sarcoma; and neoadjuvant and metastatic triple negative breast cancer which is in Phase 2 clinical trials. The company was incorporated in 2012 and is headquartered in Shelton, Connecticut. |
| Long Name | Intensity Therapeutics, Inc. |
| Market | us_market |
| Market Cap | 13,464,746 |
| Market State | POSTPOST |
| Max Age | 86,400 |
| Message Board Id | finmb_225412349 |
| Most Recent Quarter | 1,767,139,200 |
| Net Income To Common | -11,606,000 |
| Next Fiscal Year End | 1,798,675,200 |
| Non Diluted Market Cap | 13,515,809 |
| Number Of Analyst Opinions | 6 |
| Open | 5.21 |
| Operating Cashflow | -9,233,000 |
| Operating Margins | 0.0 |
| Payout Ratio | 0.0 |
| Phone | 203 221 7381 |
| Post Market Change | -0.03999996 |
| Post Market Change Percent | -0.7547162 |
| Post Market Price | 5.26 |
| Post Market Time | 1,776,469,552 |
| Previous Close | 5.32 |
| Price Eps Current Year | -1.4708618 |
| Price Hint | 2 |
| Price To Book | 1.1267008 |
| Profit Margins | 0.0 |
| Quick Ratio | 5.555 |
| Quote Source Name | Nasdaq Real Time Price |
| Quote Type | EQUITY |
| Recommendation Key | strong_buy |
| Recommendation Mean | 1.0 |
| Region | US |
| Regular Market Change | -0.02 |
| Regular Market Change Percent | -0.375939 |
| Regular Market Day High | 5.42 |
| Regular Market Day Low | 5.2 |
| Regular Market Day Range | 5.2 - 5.42 |
| Regular Market Open | 5.21 |
| Regular Market Previous Close | 5.32 |
| Regular Market Price | 5.3 |
| Regular Market Time | 1,776,456,001 |
| Regular Market Volume | 58,811 |
| Return On Assets | -0.79247004 |
| Return On Equity | -1.56901 |
| Sand P52 Week Change | 0.36506534 |
| Sector | Healthcare |
| Sector Disp | Healthcare |
| Sector Key | healthcare |
| Shares Outstanding | 2,540,518 |
| Shares Percent Shares Out | 0.024 |
| Shares Short | 61,082 |
| Shares Short Previous Month Date | 1,772,150,400 |
| Shares Short Prior Month | 71,994 |
| Short Name | Intensity Therapeutics, Inc. |
| Short Percent Of Float | 0.0249 |
| Short Ratio | 2.22 |
| Source Interval | 15 |
| State | CT |
| Symbol | INTS |
| Target High Price | 125.0 |
| Target Low Price | 12.0 |
| Target Mean Price | 41.5 |
| Target Median Price | 30.0 |
| Total Cash | 11,921,000 |
| Total Cash Per Share | 4.692 |
| Total Debt | 110,000 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | 0.0 |
| Trailing Eps | -8.56 |
| Trailing Peg Ratio | None |
| Triggerable | 1 |
| Two Hundred Day Average | 8.32342 |
| Two Hundred Day Average Change | -3.0234194 |
| Two Hundred Day Average Change Percent | -0.36324245 |
| Type Disp | Equity |
| Volume | 58,811 |
| Website | https://www.intensitytherapeutics.com |
| Zip | 06,484-4779 |